Editas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $4.29 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.